Mostrando postagens com marcador Statins. Mostrar todas as postagens
Mostrando postagens com marcador Statins. Mostrar todas as postagens

quarta-feira, 15 de julho de 2015

Treating more adults with statins would be cost-effective way to boost heart health

 

 

Treating more adults with statins may be a cost-effective way to boost heart health.

Credit: © David Watkins / Fotolia

A new study from Harvard T.H. Chan School of Public Health researchers has found that it would be cost-effective to treat 48-67% of all adults aged 40-75 in the U.S. with cholesterol-lowering statins. By expanding the current recommended treatment guidelines and boosting the percentage of adults taking statins, an additional 161,560 cardiovascular-related events could be averted, according to the researchers.

"The new cholesterol treatment guidelines have been controversial, so our goal for this study was to use the best available evidence to quantify the tradeoffs in health benefits, risks, and costs of expanding statin treatment. We found that the new guidelines represent good value for money spent on healthcare, and that more lenient treatment thresholds might be justifiable on cost-effectiveness grounds even accounting for side-effects such as diabetes and myalgia," said Ankur Pandya, assistant professor of health decision science at Harvard Chan School and lead author of the study.

The study appears online July 14, 2015 in the Journal of the American Medical Association.

The percentage of the US people taking statins has jumped in recent years -- as of 2012, 26% of all adults over age 40 were taking them, according to the U.S. Centers for Disease Control and Prevention (CDC) -- and so has controversy surrounding their use. In November 2013, the American Heart Association (AHA) and the American College of Cardiology (ACC) recommended that statins be prescribed for people with a 7.5% or greater risk of heart attack or stroke over a 10-year period, including many with no existing cardiovascular issues. Previous guidelines had advised statin use only if the risk was 10-20% or higher.

After the 2013 recommendations were issued, proponents of expanding statin use said there was strong evidence that they reduce risk of heart attack and stroke; critics said the risks were overestimated, that healthy adults would be overtreated, and that more people would be at increased risk for negative side effects, such as memory loss, type 2 diabetes, and muscle damage.

The researchers did a cost-effectiveness analysis of the ACC-AHA guidelines to find the optimal value for the 10-year CVD risk threshold. They used a measure known as the quality-adjusted life-year (QALY) -- a measure of the burden of a disease in terms of both the quality and the quantity of life lived. QALYs are frequently used to assess the monetary value of using particular medical interventions; they are based on the number of years of "quality" life that would be gained by such interventions. In the U.S. today, health economists typically consider $100,000/QALY and $150,000/QALY reasonable in terms of what the public is willing to pay for health gains.

The researchers found that the current 10-year cardiovascular disease (CVD) risk threshold (≥7.5%) was acceptable in terms of cost-effectiveness ($37,000/QALY), but that more lenient treatment thresholds of ≥4.0% or ≥3.0% would be optimal under criteria of <$100,000/QALY or <$150,000/QALY and would avert an estimated additional 125,000-160,000 CVD-events. They also found that the optimal treatment threshold was particularly sensitive to patient preferences for taking a pill daily, which suggests that the decision to initiate statins for primary CVD prevention should be made jointly by patients and physicians.

Other Harvard Chan School authors of the study included Stephen Sy and Sylvia Cho, researchers from the Center for Health Decision Science; Milton Weinstein, Henry J. Kaiser Professor of Health Policy and Management; and senior author Thomas Gaziano, assistant professor in the Department of Health Policy and Management and cardiologist at Brigham and Women's Hospital.

Funding for the study came from grant No. 5R01HL104284-03 to the Harvard T.H. Chan School of Public Health from the National Heart, Lung, and Blood Institute.


Story Source:

The above post is reprinted from materials provided by Harvard School of Public Health. Note: Materials may be edited for content and length.


Journal Reference:

  1. Ankur Pandya, Stephen Sy, Sylvia Cho, Milton C. Weinstein, Thomas A. Gaziano. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease. JAMA, 2015; 314 (2): 142 DOI: 10.1001/jama.2015.6822

quarta-feira, 15 de abril de 2015

Statins: Are these cholesterol-lowering drugs right for you?

Find out whether your risk factors for heart disease make you a good candidate for statin therapy.

By Mayo Clinic Staff

Statins are drugs that can lower your cholesterol. They work by blocking a substance your body needs to make cholesterol. Statins may also help your body reabsorb cholesterol that has built up in plaques on your artery walls, preventing further blockage in your blood vessels and heart attacks.

Statins include medications such as atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Altoprev), pitavastatin (Livalo), pravastatin (Pravachol), rosuvastatin (Crestor) and simvastatin (Zocor). Lower-cost generic versions of many statin medications are available.

Already shown to be effective in lowering cholesterol, statins may have other potential benefits. But doctors are far from knowing everything about statins. Are they right for everybody with high cholesterol? What kinds of side effects may occur? Can statins help prevent other diseases?

Should you be on a statin?

Whether you need to be on a statin depends on your cholesterol level, along with your other risk factors for cardiovascular disease.

Most people should try to keep their total cholesterol level below 200 milligrams per deciliter (mg/dL) (6.22 millimoles per liter, or mmol/L). Low-density lipoprotein cholesterol (LDL, or "bad" cholesterol) should be below 100 mg/dL (3.37 mmol/L).

But the numbers alone won't tell you or your doctor the whole story. High cholesterol is only one of a number of risk factors for heart attack and stroke.

The most important factor to consider is a person's long-term risk of experiencing a heart attack or stroke. If the risk is very low, there is probably no need for statins, unless the LDL is above 190 mg/dL (4.9 mmol/L). If the risk is very high — for example, someone who has had a heart attack in the past — the person may benefit from statins, even if his or her cholesterol is not elevated.

Risk assessment tools

Your doctor may suggest using an online tool to better understand your long-term risks of developing heart disease.

The American College of Cardiology and the American Heart Association have recently developed an online tool to predict a person's chances of having a heart attack in the next 10 years. For people under the age of 50, the Framingham cardiovascular disease risk calculator might be a better option because it provides a 30-year risk prediction.

In addition to your cholesterol numbers, these risk calculators also ask about your age, race, sex, blood pressure and whether you have diabetes or smoke cigarettes.

New cholesterol guidelines

New guidelines from the American College of Cardiology and American Heart Association focus on four main groups of people who may be helped by statins:

  • People who already have cardiovascular disease. This group includes people who have had heart attacks, strokes caused by blockages in a blood vessel, mini-strokes (transient ischemic attacks), peripheral artery disease, or prior surgery to open or replace coronary arteries.
  • People who have very high LDL (bad) cholesterol. This group includes adults who have LDL cholesterol levels of 190 mg/dL (4.9 mmol/L) or higher.
  • People who have diabetes. This group includes adults who have diabetes and an LDL between 70 and 189 mg/dL (1.8 and 4.9 mmol/L), especially if they have evidence of vascular disease.
  • People who have a higher 10-year risk of heart attack. This group includes people who have an LDL above 100 mg/dL (1.8 mmol/L) and whose 10-year risk of a heart attack is 7.5 percent or higher.
Lifestyle is still key for preventing heart disease

Lifestyle changes are essential for reducing your risk of heart disease, whether you take a statin or not. To reduce your risk:

  • Quit smoking and avoid secondhand smoke
  • Eat a healthy diet that's low in saturated fat, trans fat, refined carbohydrates and salt, and rich in fruits, vegetables, fish, and whole grains.
  • Be physically active, sit less and exercise regularly
  • Maintain a healthy waist girth: less than 40 inches in men and less than 35 inches in women

If you're following the recommended lifestyle behaviors but your cholesterol — particularly your LDL (bad) cholesterol — remains high, statins might be an option for you. Risk factors for heart disease and stroke are:

  • Smoking
  • High cholesterol
  • High blood pressure
  • Diabetes
  • Being overweight or obese
  • Family history of heart disease, especially if it was before the age of 55 in male relatives or before 65 in female relatives
  • Not exercising
  • Poor stress and anger management
  • Older age
  • Narrowing of the arteries in your neck, arms or legs (peripheral artery disease)

See more In-depth

Consider statins a lifelong commitment

You may think that once your cholesterol goes down, you can stop taking medication. But if your cholesterol levels have decreased after you take a statin, you'll likely need to stay on it indefinitely. If you stop taking it, your cholesterol levels will probably go back up.

The exception may be if you make significant changes to your diet or lose a lot of weight. Substantial lifestyle changes may help you lower your cholesterol without continuing to take the medication, but don't make any changes to your medications without talking to your doctor first.

The side effects of statins

Although statins are well-tolerated by most people, they do have side effects, some of which may go away as your body adjusts to the medication.

Common, less serious side effects
  • Muscle and joint aches (most common)
  • Headache
  • Nausea
Rare but potentially serious side effects
  • Muscle problems. Statins may cause muscle pain and tenderness, particularly if you're taking a high dosage. In severe cases, muscle cells can break down (rhabdomyolysis) and release a protein called myoglobin into the bloodstream. Myoglobin can damage your kidneys.
  • Liver damage. Occasionally, statin use causes an increase in liver enzymes. If the increase is only mild, you can continue to take the drug. Contact your doctor immediately if you have unusual fatigue or weakness, loss of appetite, pain in your upper abdomen, dark-colored urine, or yellowing of your skin or eyes.
  • Increased blood sugar or type 2 diabetes. It's possible your blood sugar (blood glucose) level may increase when you take a statin, which may lead to developing type 2 diabetes.
  • Cognitive problems. Some people have experienced memory loss and confusion after using statins. However, scientific studies have failed to prove that statins actually cause cognitive problems.

It's important to consider the effects of statins on other organs in your body, especially if you have health problems such as liver or kidney disease. Also, check whether statins interact with any other prescription or over-the-counter drugs or supplements you take.

Keep in mind that when you begin to take a statin, you'll most likely be on it for the rest of your life. Side effects are often minor, but if you experience them, you may want to talk to your doctor about decreasing your dose or trying a different statin. Don't stop taking a statin without talking to your doctor first.

What other benefits do statins have?

Statins may have benefits other than just lowering your cholesterol. One promising benefit of statins appears to be their anti-inflammatory properties, which help stabilize the lining of blood vessels. This has potentially far-reaching effects, from the brain and heart to blood vessels and organs throughout the body.

In the heart, stabilizing the blood vessel linings would make plaques less likely to rupture, thereby reducing the chance of a heart attack. Statins also help relax blood vessels, lowering blood pressure.

Weighing the risks and benefits of statins

When thinking about whether you should take statins for high cholesterol, ask yourself these questions:

  • Do I have other risk factors for cardiovascular disease?
  • Am I willing and able to make lifestyle changes to improve my health?
  • Am I concerned about taking a pill every day, perhaps for the rest of my life?
  • Am I concerned about statins' side effects or interactions with other drugs?

It's important to take into account not only your medical reasons for a decision, but also your personal values and concerns. Talk to your doctor about your total risk of cardiovascular disease and discuss how your lifestyle and preferences play a role in your decision about taking medication for high cholesterol.

 

sexta-feira, 14 de novembro de 2014

Common cholesterol-fighting drug may prevent hysterectomies in women with uterine fibroids

 

November 13, 2014

University of Texas Medical Branch at Galveston

The cholesterol-lowering drug simvastatin inhibits the growth of human uterine fibroid tumors, researchers have discovered for the first time. Statins, such as simvastatin, are commonly prescribed to lower high cholesterol levels. Beyond these well-known cholesterol-lowering abilities, statins also combat certain tumors. Statins have previously been shown to have anti-tumor effects on breast, ovarian, prostate, colon, leukemia and lung cancers. The effect of statins on uterine fibroids was unknown.


Researchers at the University of Texas Medical Branch at Galveston, in collaboration with The University of Texas Health Science Center at Houston (UTHealth), Baylor College of Medicine and the Georgia Regents University, report for the first time that the cholesterol-lowering drug simvastatin inhibits the growth of human uterine fibroid tumors. These new data are published online and scheduled to appear in the January print edition of the Journal of Biological Chemistry.

Statins, such as simvastatin, are commonly prescribed to lower high cholesterol levels. Statins work by blocking an early step in cholesterol production.

Beyond these well-known cholesterol-lowering abilities, statins also combat certain tumors. Statins have previously been shown to have anti-tumor effects on breast, ovarian, prostate, colon, leukemia and lung cancers. The effect of statins on uterine fibroids was unknown.

"Non-cancerous uterine fibroids are the most common type of tumor in the female reproductive system, accounting for half of the 600,000 hysterectomies done annually in the U.S. Their estimated annual cost is up to $34 billion in the U.S. alone," said UTMB's Dr. Mostafa Borahay, assistant professor in the department of obstetrics and gynecology and lead author. "Despite this, the exact cause of these tumors is not well understood, as there are several genetic, familial and hormonal abnormalities linked with their development."

The study investigated the impact of simvastatin on human uterine fibroid cell growth. The researchers revealed that simvastatin impedes the growth of uterine fibroid tumor cells. The researchers also studied the way simvastatin works to suppress these tumors. Simvastatin was shown to inhibit ERK phosphorylation, which is a critical step in the molecular pathway that prompts the growth of new cells. In addition, simvastatin stops the progression of tumor cells that have already begun to grow and induces calcium-dependent cell death mechanisms in fibroid tumor cells.

"Taken together, this study has identified a novel pathway by which simvastatin induces the death of uterine fibroid tumor cells." said Darren Boehning, associate professor in the department of biochemistry and molecular biology at the UTHealth Medical School, adjunct professor in the department of neuroscience and cell biology at UTMB and member of The University of Texas Graduate School of Biomedical Sciences at Houston.

"The findings of this study are particularly significant; statins have been in clinical use for years so their safety profile is well known," said Dr. Borahay. "Having a safe medicine to treat these common tumors has been a goal for women and the medical community for a long time."

"The research team is currently studying the effects of statins in fibroid animal models and adopting nanotechnology to enhance the drug delivery to the tumor," said Chandrasekhar Yallampalli, professor in the department of obstetrics and gynecology at Baylor College of Medicine.


Story Source:

The above story is based on materials provided by University of Texas Medical Branch at Galveston. Note: Materials may be edited for content and length.


Journal Reference:

  1. M. A. Borahay, G. S. Kilic, C. Yallampalli, R. R. Snyder, G. D. V. Hankins, A. Al-Hendy, D. Boehning. Simvastatin Potently Induces Calcium-Dependent Apoptosis of Human Leiomyoma Cells. Journal of Biological Chemistry, 2014; DOI: 10.1074/jbc.M114.583575

 

segunda-feira, 22 de setembro de 2014

Statin use during hospitalization for hemorrhagic stroke associated with improved survival

 


Patients who were treated with a statin in the hospital after suffering from a hemorrhagic stroke were significantly more likely to survive than those who were not, according to a study published today in JAMA Neurology. This study was conducted by the same researchers who recently discovered that the use of cholesterol-lowering statins can improve survival in victims of ischemic stroke.

Ischemic stroke is caused by a constriction or obstruction of a blood vessel that blocks blood from reaching areas of the brain, while hemorrhagic stroke, also known as intracerebral hemorrhage, is bleeding in the brain.

"Some previous research has suggested that treating patients with statins after they suffer hemorrhagic stroke may increase their long-term risk of continued bleeding," said lead author Alexander Flint, MD, PhD, of the Kaiser Permanente Department of Neuroscience in Redwood City, Calif. "Yet the findings of our study suggest that stopping statin treatments for these patients may carry substantial risks."

The study included 3,481 individuals who were admitted to any of 20 Kaiser Permanente hospitals in Northern California with a hemorrhagic stroke over a 10-year period. Researchers looked at patient survival and discharge 30 days after the stroke.

Patients treated with a statin while in the hospital were more likely to be alive 30 days after suffering a hemorrhagic stroke than those who were not treated with a statin — 81.6 percent versus 61.3 percent. Patients treated with a statin while in the hospital were also more likely to be discharged to home or an acute rehabilitation facility than those who were not — 51.1 percent compared to 35.0 percent.

Patients whose statin therapy was discontinued — that is, patients taking a statin as an outpatient prior to experiencing a hemorrhagic stroke who did not receive a statin as an inpatient — had a mortality rate of 57.8 percent compared with a mortality rate of 18.9 percent for patients using a statin before and during hospitalization.

The researchers concluded that statin use is strongly associated with improved outcomes after hemorrhagic stroke, and that discontinuing statin use is strongly associated with worsened outcomes after hemorrhagic stroke.

Kaiser Permanente can conduct transformational health research in part because it has the largest private, patient-centered electronic health system in the world. The organization's electronic health record system, Kaiser Permanente HealthConnect®, securely connects approximately 9.5 million patients to more than 17,000 physicians in more than 600 medical offices and 38 hospitals. It also connects Kaiser Permanente's research scientists to one of the most extensive collections of longitudinal medical data available, facilitating studies and important medical discoveries that shape the future of health and care delivery for patients and the medical community.


Story Source:

The above story is based on materials provided by Kaiser Permanente. Note: Materials may be edited for content and length.


Journal Reference:

  1. Alexander C. Flint, Carol Conell, Vivek A. Rao, Jeff G. Klingman, Stephen Sidney, S. Claiborne Johnston, J. Claude Hemphill, Hooman Kamel, Stephen M. Davis, Geoffrey A. Donnan. Effect of Statin Use During Hospitalization for Intracerebral Hemorrhage on Mortality and Discharge Disposition. JAMA Neurology, 2014; DOI: 10.1001/jamaneurol.2014.2124